Dublin, Feb. 15, 2022 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Business Outlook" report has been added to ResearchAndMarkets.com's offering.
The Twice-Monthly Publication Cell and Gene Therapy Business Outlook will offer the following:
- Market Sizing and Forecasting of CAGT Markets: Each issue sizes up the market opportunity and projects the future revenues for a given therapeutic segment.
- Keeping an Eye on Financing: With billions of investment dollars announced each year, Cell and Gene Therapy Business Outlook tracks who is getting financed (and the companies behind the financing) each issue. On a regular basis we will analyze trends in that financing.
- News Briefs and Analysis of the Science That will Shape Tomorrow's Business: Cell and Gene Therapy Business Outlook is designed to provide the most relevant news. With a focus on what the recent news of the day means for business, our curated news and news analysis means that you and your organization can be confident you won't miss an important development in cell and gene therapy.
- Deals Between CAGT Companies Tracked: Each issue's "Recent Deals Table" tracks the important deals between stem cell companies as well as the deals they engage in (tech transfers, partnerships, mergers, distribution and other activities) with companies outside the industry.
- Cell and Gene Therapy Tools: This newsletter will also report on developments, product launches and deals relating to the makers of cell and gene therapy manufacturing equipment and supplies.
Target Audience Includes:
- Director, Vice President or Manager of Market Research
- Director, Vice President or Manager of Marketing
- Director, Vice President or Manager of Research and Development
- Director of Business Insights
- Director of Business Development
- CEO
For more information about this report visit https://www.researchandmarkets.com/r/fqbvuo
